Compare ASH & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASH | WVE |
|---|---|---|
| Founded | 1924 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | N/A | 2015 |
| Metric | ASH | WVE |
|---|---|---|
| Price | $62.24 | $13.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $66.29 | $30.56 |
| AVG Volume (30 Days) | 673.3K | ★ 3.8M |
| Earning Date | 02-02-2026 | 03-03-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,805,000,000.00 | $109,230,000.00 |
| Revenue This Year | $3.34 | N/A |
| Revenue Next Year | $3.55 | $16.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 103.75 |
| 52 Week Low | $45.21 | $5.28 |
| 52 Week High | $67.39 | $21.73 |
| Indicator | ASH | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 48.95 |
| Support Level | $57.87 | $12.70 |
| Resistance Level | $64.55 | $14.56 |
| Average True Range (ATR) | 1.97 | 0.78 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 59.42 | 53.73 |
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.